Last reviewed · How we verify
P. falciparum IBSM infection
At a glance
| Generic name | P. falciparum IBSM infection |
|---|---|
| Sponsor | Medicines for Malaria Venture |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum (PHASE1)
- Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria (PHASE1)
- A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- P. falciparum IBSM infection CI brief — competitive landscape report
- P. falciparum IBSM infection updates RSS · CI watch RSS
- Medicines for Malaria Venture portfolio CI